--- title: "Tempest Therapeutics | 10-Q: FY2026 Q1 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/286468845.md" datetime: "2026-05-14T21:05:40.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286468845.md) - [en](https://longbridge.com/en/news/286468845.md) - [zh-HK](https://longbridge.com/zh-HK/news/286468845.md) --- # Tempest Therapeutics | 10-Q: FY2026 Q1 Revenue: USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0. EPS: As of FY2026 Q1, the actual value is USD -2.53. EBIT: As of FY2026 Q1, the actual value is USD -27.74 M. Tempest Therapeutics, Inc. operates as a single reportable and operating segment, focusing on the discovery and development of cell therapy and small molecule product candidates . #### Operating Results (Three Months Ended March 31) - \#### Net LossTempest Therapeutics, Inc. reported a net loss of - $27,696 thousand for the three months ended March 31, 2026, which is a 155% increase compared to - $10,860 thousand for the same period in 2025 . - \#### Loss from OperationsThe loss from operations increased by 153% to - $27,719 thousand in 2026 from - $10,936 thousand in 2025 . - \#### Research and Development ExpensesThese expenses decreased by 99% to $114 thousand in 2026 from $7,627 thousand in 2025, primarily due to re-prioritizing efforts towards strategic alternatives and the subsequent Asset Acquisition . Candidate specific research costs decreased by 99% to $59 thousand in 2026 from $4,795 thousand in 2025 . Personnel and other costs decreased by 100% to $10 thousand in 2026 from $2,181 thousand in 2025 . Stock-based compensation and depreciation decreased by 93% to $45 thousand in 2026 from $651 thousand in 2025 . - \#### General and Administrative ExpensesThese expenses increased by 64% to $5,425 thousand in 2026 from $3,309 thousand in 2025, mainly due to one-time costs from the Asset Acquisition . - \#### Acquired In-Process Research and DevelopmentTempest Therapeutics, Inc. incurred $22,180 thousand in acquired in-process research and development expenses in 2026, compared to none in 2025 . - \#### Interest ExpenseNo interest expense was incurred in 2026, down from - $161 thousand in 2025, as the Oxford Loan was repaid in April 2025 . - \#### Interest Income and Other Income (Expense), NetThis decreased by 90% to $23 thousand in 2026 from $237 thousand in 2025 . #### Liquidity and Capital Resources - \#### Cash and Cash EquivalentsAs of March 31, 2026, Tempest Therapeutics, Inc. had $1,805 thousand in cash and cash equivalents, a decrease from $7,707 thousand as of December 31, 2025 . - \#### Accumulated DeficitThe accumulated deficit as of March 31, 2026, was - $270,072 thousand . - \#### Cash Used in Operating ActivitiesCash used in operating activities was - $7,598 thousand for the three months ended March 31, 2026, compared to - $8,036 thousand for the same period in 2025 . - \#### Cash Provided by Financing ActivitiesCash provided by financing activities was $1,696 thousand for the three months ended March 31, 2026, compared to cash used of - $721 thousand for the same period in 2025 . This included $1,272 thousand from the issuance of common stock, pre-funded warrants, and common stock warrants, and $424 thousand from related parties . - \#### Net Decrease in CashThe net decrease in cash, cash equivalents, and restricted cash was - $5,902 thousand for the three months ended March 31, 2026, compared to - $8,757 thousand for the same period in 2025 . #### Strategic Summary and Outlook Tempest Therapeutics, Inc. expanded its pipeline in February 2026 by acquiring rights to a portfolio of dual-targeting CAR-T cell therapy product candidates, including TPST-2003, TPST-2206, TPST-3003, and TPST-3206 . The company also maintains small-molecule product candidates, Amezalpat, which is Phase 3-ready for hepatocellular carcinoma, and TPST-1495, for which a Phase 2 study in familial adenomatous polyposis is expected to be initiated in 2026, funded by the National Cancer Institute . Tempest Therapeutics, Inc. expects its existing cash and cash equivalents to fund operations for less than 12 months, leading to substantial doubt about its ability to continue as a going concern, necessitating additional financing . Factor Bioscience Inc. has a funding commitment of up to $20.0 million, with $13.8 million remaining available as of March 31, 2026, although there is uncertainty regarding satisfying the conditions for accessing these funds . In May 2026, Factor Bioscience Inc. waived $2.1 million in payment obligations and returned a $0.2 million deposit to Tempest Therapeutics, Inc. to enhance its cash runway . ### Related Stocks - [TPST.US](https://longbridge.com/en/quote/TPST.US.md) ## Related News & Research - [Tempest Therapeutics Q1 net loss widens on asset acquisition costs](https://longbridge.com/en/news/286464103.md) - [Atrium Therapeutics Reports First Quarter 2026 Financial Results | RNA Stock News](https://longbridge.com/en/news/286465472.md) - [LifeSci Capital Sticks to Its Buy Rating for Spyre Therapeutics (SYRE)](https://longbridge.com/en/news/286679543.md) - [Pelthos Therapeutics GAAP EPS of -$3.09, revenue of $10.7M](https://longbridge.com/en/news/286430906.md) - [Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics | NBIX Stock News](https://longbridge.com/en/news/286773551.md)